AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
AVROBIO, Inc. (AVRO) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -97,425,000 | 6.35 M | 101.09 M | 100.26 M | |
| 2022 | 269 K | -75,101,000 | 28.58 M | 103.95 M | 99.68 M |
| 2021 | 2.7 M | -174,622,000 | 34.36 M | 203.84 M | 199.15 M |
| 2020 | 2.56 M | -259,682,000 | 16.89 M | 271.23 M | 267.24 M |
| 2019 | 2.14 M | -187,043,000 | 14.5 M | 200.51 M | 195.7 M |